苑东生物:HP-002片完成I/II期临床首例受试者入组给药

智通财经
Aug 12
【苑东生物:HP-002片完成I/II期临床首例受试者入组给药】苑东生物公告,公司控股子公司上海超阳药业自主研发的化学药品1类创新药HP-002片,用于治疗复发或难治的B细胞非霍奇金淋巴瘤的I/II期临床试验,于近日完成首例受试者入组给药。该药物于2026年5月29日获国家药监局临床试验批准,本次启动的I期剂量递增阶段已完成首例入组。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10